Antiangiogenic activity of 2-deoxy-D-glucose

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Merchan, Jaime R ^a   Kovács, Krisztina ^a   Railsback, Jaclyn W ^a   Kurtoglu, Metin ^a   Jing, Yuqi ^a   Piña, Yolanda ^b   Gao, Ningguo ^c   Murray, Timothy G ^b   Lehrman, Mark A ^c   Lampidis, Theodore J ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; FLUORODEOXYGLUCOSE; GLUCOSE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MANNOSE; MATRIGEL; OLIGOSACCHARIDE; OXAMIC ACID; ANGIOGENESIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CAPILLARY; CARBOHYDRATE SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GLYCOLYSIS; GLYCOSYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ENDOTHELIUM; METABOLIC INHIBITION; MIGRATION INHIBITION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; NONHUMAN; PROTEIN INDUCTION; PROTEIN METABOLISM; RETINOBLASTOMA; TRANSGENIC MOUSE; UMBILICAL VEIN; UNFOLDED PROTEIN RESPONSE; ANIMAL; IMMUNOHISTOCHEMISTRY; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DEOXYGLUCOSE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC;

EID: 78149450359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013699     Document Type: Article

References (53)

1. Cao Y (2010) Angiogenesis: What can it offer for future medicine? Exp Cell Res 316: 1304-1308.
2. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
3. Davidson SM, Duchen MR (2007) Endothelial mitochondria: contributing to vascular function and disease. Circ Res 100: 1128-1141.
4. Mann GE, Yudilevich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83: 183-252.
5. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
6. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
7. Gatenby RA, Gillies RJ (2007) Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39: 1358-1366.
8. Kim JW, Dang CV (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66: 8927-8930.
9. Maschauer S, Prante O, Hoffmann M, Deichen JT, Kuwert T (2004) Characterization of 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med 45: 455-460.
10. Abaci HE, Truitt R, Luong E, Drazer G, Gerecht S (2010) Adaptation to oxygen deprivation in cultures of human pluripotent stem cells, endothelial progenitor cells, and umbilical vein endothelial cells. Am J Physiol Cell Physiol 298: C1527-1537.
11. Loike JD, Cao L, Brett J, Ogawa S, Silverstein SC, et al. (1992) Hypoxia induces glucose transporter expression in endothelial cells. Am J Physiol 263: C326-333.
12. Yeh WL, Lin CJ, Fu WM (2008) Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia. Mol Pharmacol 73: 170-177.
13. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A (2002) 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 32: 70-76.
14. Belhocine T, Blockmans D, Hustinx R, Vandevivere J, Mortelmans L (2003) Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging 30: 1305-1313.
15. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, et al. (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20: 379-387.
16. Buck AK, Reske SN (2004) Cellular origin and molecular mechanisms of 18F-FDG uptake: is there a contribution of the endothelium? J Nucl Med 45: 461-463.
17. Datema R, Schwarz RT (1979) Interference with glycosylation of glycoproteins. Inhibition of formation of lipid-linked oligosaccharides in vivo. Biochem J 184: 113-123.
18. Kurtoglu M, Maher JC, Lampidis TJ (2007) Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal 9: 1383-1390.
19. Aft RL, Zhang FW, Gius D (2002) Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 87: 805-812.
20. Boutrid H, Jockovich ME, Murray T, Pina Y, Feuer WJ, et al. (2008) Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma. Invest Ophthalmol Vis Sci.
21. Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, et al. (2007) Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 6: 3049-3058.
22. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, et al. (2004) 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34.
23. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, et al. (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70: 1388-1394.
24. Raez LE, Langmuir V, Tolba K, Rocha-Lima CM, Papadopoulos K, Kroll S, et al. (2007) Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/ N) carcinomas. In: OncologyJoC, ed;2007 June 20.
25. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, et al. (1996) Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35: 103-111.
26. Chan B, Merchan JR, Kale S, Sukhatme VP (2003) Antiangiogenic property of human thrombin. Microvasc Res 66: 1-14.
27. Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP (2003) In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 95: 388-399.
28. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.
29. Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ (2007) Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 6: 732-741.
30. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, et al. (2001) Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem 276: 31959-31968.
31. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, et al. (2000) Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275: 21340-21348.
32. Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100: 12917-12922.
33. Chander SK, Foster PA, Leese MP, Newman SP, Potter BV, et al. (2007) In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 96: 1368-1376.
34. Windle JJ, Albert DM, O'Brien JM, Marcus DM, Disteche CM, et al. (1990) Retinoblastoma in transgenic mice. Nature 343: 665-669.
35. Jockovich ME, Bajenaru ML, Pina Y, Suarez F, Feuer W, et al. (2007) Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. Invest Ophthalmol Vis Sci 48: 2476-2482.
36. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W (2006) Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci 47: 1264-1268.
37. Sone H, Deo BK, Kumagai AK (2000) Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Invest Ophthalmol Vis Sci 41: 1876-1884.
38. Kaufman RJ (2002) Orchestrating the unfolded protein response in health and disease. J Clin Invest 110: 1389-1398.
39. Marback EF, Arias VE, Paranhos A, Jr., Soares FA, Murphree AL, et al. (2003) Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol 87: 1224-1228.
40. Rossler J, Dietrich T, Pavlakovic H, Schweigerer L, Havers W, et al. (2004) Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol 164: 391-394.
41. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
42. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
43. Maher JC, Savaraj N, Priebe W, Liu H, Lampidis TJ (2005) Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 30: e34-39.
44. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
45. Krutzfeldt A, Spahr R, Mertens S, Siegmund B, Piper HM (1990) Metabolism of exogenous substrates by coronary endothelial cells in culture. J Mol Cell Cardiol 22: 1393-1404.
46. Martinez JA, Tavarez JJ, Oliveira CM, Banerjee DK (2006) Potentiation of angiogenic switch in capillary endothelial cells by cAMP: A cross-talk between up-regulated LLO biosynthesis and the HSP-70 expression. Glycoconj J 23: 209-220.
47. Martinez JA, Torres-Negron I, Amigo LA, Banerjee DK (1999) Expression of Glc3Man9GlcNAc2-PP-Dol is a prerequisite for capillary endothelial cell proliferation. Cell Mol Biol (Noisy-le-grand) 45: 137-152.
48. Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ, et al. (1995) The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res 55: 2920-2926.
49. Martinez JA, Torres-Negron I, Amigo LA, Roldan RA, Mendez A, et al. (2000) Tunicamycin inhibits capillary endothelial cell proliferation by inducing apoptosis. Targeting dolichol-pathway for generation of new anti-angiogenic therapeutics. Adv Exp Med Biol 476: 197-208.
50. Bourke CA, Carrigan MJ (1993) Experimental tunicamycin toxicity in cattle, sheep and pigs. Aust Vet J 70: 188-189.
51. Lin TY, Wang SM, Fu WM, Chen YH, Yin HS (1999) Toxicity of tunicamycin to cultured brain neurons: ultrastructure of the degenerating neurons. J Cell Biochem 74: 638-647.
52. Ruprecht RM, Mullaney S, Andersen J, Bronson R (1989) In vivo analysis of castanospermine, a candidate antiretroviral agent. J Acquir Immune Defic Syndr 2: 149-157.
53. Saul R, Ghidoni JJ, Molyneux RJ, Elbein AD (1985) Castanospermine inhibits alpha-glucosidase activities and alters glycogen distribution in animals. Proc Natl Acad Sci USA 82: 93-97.